Revance Therapeutics 株価情報 (NASDAQ: RVNC)

最新ニュース Revance Therapeutics (NASDAQ:RVNC) 株価情報

Revance Therapeutics

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Inc

<ul>
<li>Increased offer price to $3.65 per share, a $0.55 per share increase</li>
<li>Improved offer unanimously approved by Revance Board of Directors</li>
<li>Crown to extend tender offer until 11:59 p.m., Eastern Time, on February 4, 2025</li>
<li>Crown's offer is the only fully-financed offer currently available to Revance's stockholders</li>
<li>Outside termination date under the A&amp;R Merger Agreement is February 7, 2025</li>
</ul>
Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) ("Revance"), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the "Second Amendment," together with the Amended and Restated Merger Agreement, dated December 7, 2024, the "A&amp;R Merger Agreement").
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250121493847/en/">https://www.businesswire.com/news/home/20250121493847/en/</a>
Under the terms of the Second Amendment, which has been unanimously approved by the Revance Board of Directors, Revance's stockholders will receive $3.65 per share of common stock, par value $0.001 per share (each, a "Share") in cash, without interest and less any applicable tax withholding, representing $0.55 or 17% per share more than the prior offer price. Crown will extend its existing tender offer for all of Revance's outstanding Shares until one minute past 11:59 p.m., Eastern Time, on February 4, 2025.

RVNC

Crown Laboratories And Revance Amend The A&R Merger Agreement To Increase Offer Price To $3.65 Per Share, A $0.55 Per Share Increase And Extend Existing Tender Offer

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

News

ABBV

BIIB

LNTH

NGVT

NPSCY

SAGE

SANW

SLRX

TMUS

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

Needham analyst Serge Belanger reiterates Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Revance Therapeuticsto Hold

Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of&nbsp;Revance, at a price of $3.10 per Share in cash, without interest and less any applicable tax withholding.

Crown Laboratories Extension Of Tender Offer To Acquire Revance Therapeutics, Inc. At A Price Of $3.10 Per Share In Cash

WIIM

Revance Therapeutics shares are trading higher after the company announced Teoxane SA submitted a proposal to acquire the company for $3.60 per share in cash.

Teoxane SA Submits Proposal To Acquire Revance For $3.60 Per Share In Cash; Proposal Represents Premium Over $3.10 Agreement With Crown Laboratories

Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Equal-Weight and lowers the price target from $7 to $3.

Price Target

Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3

Board of Directors of Revance Recommend Stockholders Tender their Shares
JOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at a price of $3.10 per share in cash. The tender offer is being made in connection with the Amended and Restated Merger Agreement, dated December 7, 2024 (as amended or supplemented from time to time, the "A&amp;R Merger Agreement").

Crown Laboratories Announces That It Has Commenced A Cash Tender Offer To Acquire All Outstanding Shares Of Common Stock Of Revance Therapeutics At A Price Of $3.10 Per Share In Cash

Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Neutral and lowers the price target from $6.66 to $3.1.

Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $3.1

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock rose 110.0% to $4.41 during Monday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) stock rose 34.05% to $2.48. The market value of their outstanding shares is at $92.8 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 25.17% to $1.84. The company's market cap stands at $148.9 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares increased by 20.82% to $14.39. The company's market cap stands at $118.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 16.71% to $3.77. The market value of their outstanding shares is at $15.9 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares increased by 14.22% to $8.94. The company's market cap stands at $470.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) stock decreased by 72.1% to $5.6 during Monday's pre-market session. The company's market cap stands at $200.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 51.33% to $1.65. The company's market cap stands at $2.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 40.22% to $11.3. The company's market cap stands at $24.5 billion. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 20.69% to $3.03. The company's market cap stands at $317.8 million. </li>
<li>Invizyne Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZTC#NASDAQ">IZTC</a>) shares fell 18.36% to $10.81. The market value of their outstanding shares is at $103.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.46% to $1.98. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIOA

CRVO

IPHA

IZTC

RADX

SONN

STRM

12 Health Care Stocks Moving In Monday's Pre-Market Session

Revance shares are trading lower after the company announced an amended and restated merger agreement with Crown Laboratories, under which Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $3.10 per share in cash.

Crown Laboratories And Revance Enter Amended And Restated Merger Agreement; Under Terms Of Amended And Restated Agreement, Crown Will Commence Tender Offer To Acquire All Outstanding Shares Of Revance's Common Stock For $3.10 Per Share In Cash

Revance Therapeutics Extends Tender Offer Deadline With Crown Laboratories And Reba Merger Sub To December 9 Amid Ongoing Discussions, With Potential For Further Delays Or Modifications To Merger Agreement Terms, Including Offer Price Adjustments

Revance Therapeutics Extends Tender Offer Deadline For Merger With Crown Laboratories To December 3, 2024 Amid Ongoing Discussions

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) rose sharply during Monday's session following <a href="https://www.benzinga.com/news/earnings/24/11/41900813/tyson-foods-q4-earnings-revenue-and-eps-beat-beef-gains-outshine-chicken-dip-more">upbeat quarterly earnings</a>.
The company reported fourth-quarter adjusted earnings per share of 92 cents beating the street view 69 cents. Quarterly revenues of $13.565 billion (+1.6%) outpaced the analyst consensus of $13.392 billion.
Tyson shares jumped 8.5% to close at $63.79 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares surged 39.8% to $2.2781. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 33.6% to $1.5827.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 30.2% to $9.57 after the company reported better-than-expected third-quarter financial results. Also, UBS initiated coverage on the stock with a Buy rating and announced a price target of $26.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) gained 25.5% to $112.97 following strong quarterly sales.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) rose 19% to $4.1300.</li>
<li>Priority Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) gained 16.7% to $8.63.</li>
<li>Alight, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALIT#NYSE">ALIT</a>) shares rose 13.6% to $8.48 after the company reported better-than-expected third-quarter sales results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates..</li>
<li>Grab Holdings Limite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 11.7% to $4.8990 after the company reported better-than-expected quarterly financial results and raised its FY25 revenue guidance above estimates.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) gained 10.8% to $108.00 after the company reported better-than-expected third-quarter sales, despite a miss on EPS estimates..</li>
<li>The Buckle, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) rose 5.4% to $47.57 after UBS upgraded the stock from Sell to Neutral and raised its price target from $31 to $46.</li>
<li>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) gained 4.4% to $129.21 following third-quarter results. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Markets

Trading Ideas

ALIT

GRAB

NWTN

PRTH

SHOP

TSHA

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 75.3% to $0.46 during Friday's pre-market session. The company's market cap stands at $2.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock rose 29.94% to $56.42. The company's market cap stands at $10.4 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock rose 26.31% to $22.8. The market value of their outstanding shares is at $2.0 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) shares moved upwards by 20.39% to $3.01. The company's market cap stands at $237.4 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock rose 15.11% to $1.37. The company's market cap stands at $13.9 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares rose 14.99% to $1.15. The company's market cap stands at $89.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock declined by 51.8% to $0.69 during Friday's pre-market session. The company's market cap stands at $13.1 million. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) stock decreased by 40.06% to $4.7. The market value of their outstanding shares is at $665.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock decreased by 38.75% to $15.05. The market value of their outstanding shares is at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock fell 33.34% to $1.86. The market value of their outstanding shares is at $765.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 29.7% to $0.69. The market value of their outstanding shares is at $79.6 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 25.61% to $4.3. The company's market cap stands at $447.9 million. The company's, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVR

CTMX

DOCS

FTRE

INDP

MRVI

PRPH

TIVC

TNYA

12 Health Care Stocks Moving In Friday's Pre-Market Session

Needham analyst Serge Belanger reiterates Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Hold.

Needham Reiterates Hold on Revance Therapeutics

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Neutral and maintains $6.6 price target.

HC Wainwright & Co. Reiterates Neutral on Revance Therapeutics, Maintains $6.6 Price Target

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock rose 39.8% to $0.36 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock increased by 33.57% to $24.11. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock moved upwards by 32.05% to $20.39. The market value of their outstanding shares is at $358.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares increased by 21.59% to $3.2. The company's market cap stands at $83.1 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 19.31% to $0.45. The market value of their outstanding shares is at $6.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 18.7% to $3.3. The company's market cap stands at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 48.1% to $0.74 during Friday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 41.11% to $14.47. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 37.31% to $4.92. The market value of their outstanding shares is at $695.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock fell 36.6% to $3.67. The company's market cap stands at $381.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 32.08% to $1.9. The market value of their outstanding shares is at $779.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock decreased by 29.23% to $0.69. The market value of their outstanding shares is at $80.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNOX

NOTV

RIGL

12 Health Care Stocks Moving In Friday's Intraday Session

Revance Therapeutics shares are trading lower after the company reported better-than-expected Q3 EPS results.

Needham analyst Serge Belanger has maintained their neutral stance on RVNC stock, giving a Hold rating on January 13. Serge Belanger has given his ...

Hold Rating Recommended Amid Competitive Bidding War for Revance Therapeutics

Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on January 17. Uy Ear has given his Hold r...

Hold Rating Maintained Amidst Revised Acquisition Proposal for Revance Therapeutics

Revance (RVNC) and Crown Laboratories amended their Amended and Restated Merger Agreement. Under the terms of the Second Amendment, which has been ...

Revance and Crown Laboratories amend merger agreement increasing share offer

Crown Laboratories hikes offer price for Revance to $3.65/share, extends existing tender offer

Mizuho Securities analyst Uy Ear maintained a Hold rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of $3.6...

Mizuho Securities Remains a Hold on Revance Therapeutics (RVNC)

Key deals this week: Paramount Global, Toronto-Dominion Bank, Beacon Roofing Supply and more

Teoxane withdraws takeover offer for Revance Therapeutics

Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on January 17. Uy Ear's rating is based on...

Hold Rating Maintained Amidst Revance Therapeutics Acquisition Uncertainty

Revance (RVNC) and Crown Laboratories reminded Revance stockholders of the recommendation to tender their shares in support of Crown's cash tender ...

Revance's board urges stockholders to vote in favor of Crown's acquisition offer

Revance Therapeutics ( ($RVNC) ) has issued an update. On February 6, 2025, Revance Therapeutics finalized a merger with Crown Laboratories, result...

Revance Therapeutics Finalizes Merger with Crown Laboratories

BECN

PARA

Press Releases

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

Legal

Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors – Contact Levi & Korsinsky

Crown Laboratories Completes Acquisition of Revance Therapeutics

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders

DEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Therapeutics, Inc. Lawsuit – RVNC

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm

March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against  RVNC

Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC

Comments

Revance Therapeutics

ニュース

最新ニュース Revance Therapeutics (NASDAQ:RVNC) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル